Henry Meds vs Mochi Health: Compounded GLP-1 Provider Comparison
Both offer compounded semaglutide and tirzepatide at lower price points than brand-name. Mochi accepts insurance and uses obesity medicine specialists; Henry is faster to onboard. Both operate in evolving FDA regulatory environment.
Informational comparison only — not medical advice. Your prescriber decides what's right for you.
FDA Compliance Notice
Henry Meds offers compounded GLP-1 medications. As of March 2026, the FDA has issued warning letters to multiple telehealth providers regarding compounded GLP-1 marketing. Discuss FDA-approved alternatives with your provider.
Learn more →We don't currently recommend either Henry Meds or Mochi Health.
They stay in this comparison because readers search for them, but we don't link to them as partners. See the providers we do recommend →
From
$199/mo
Score
6.0/10
From
$79/mo
Score
7.0/10
Quick answer
Both offer compounded semaglutide and tirzepatide at lower price points than brand-name. Mochi accepts insurance and uses obesity medicine specialists; Henry is faster to onboard. Both operate in evolving FDA regulatory environment.
- Henry Meds FDA-approved for: See FDA label
- Mochi Health FDA-approved for: See FDA label
- Henry Meds starting price: $199/month
- Mochi Health starting price: $79/month
Quick visual breakdown
Henry Meds wins 0 · Mochi Health wins 2
Henry Meds
0 of 4 wins
Mochi Health
2 of 4 wins
Side-by-side comparison
Neutral comparator. We run no clinic and never sell medication — we earn the same commission whoever you pick, so this ranking is editorial, not pay-to-rank. Methodology · How we make money
Where to start
Ranked by our editorial score. We earn a commission if you start a consultation through these links — it never changes your price.
$145/mo
Get from $145/mo$99/mo
Get from $99/mo$99/mo
Get from $99/mo$89/mo
Get from $89/mo
People also compare
Further reading (authoritative sources)
- Prescription medications to treat overweight & obesity — NIH — NIDDKGovernment overview of approved weight-management drugs.
- GLP-1 agonists — overview & how they work — NIH — MedlinePlus
- FDA's concerns with unapproved GLP-1 drugs used for weight loss — U.S. FDA
- Medicaid coverage of and spending on GLP-1s — KFFState-by-state coverage data (2026).